Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Growth Hormone Deficiency (Apr 2021)

Posted by Matt Breese on Apr 16, 2021

Find me on:

According to our recent payer coverage analysis for growth hormone deficiency (GHD) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for growth hormone deficiency treatments shows that under the pharmacy benefit, about 55% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Growth Hormone-2Q202Data snapshot as of Q2 2021

Trends: When the FDA approved Novo Nordisk, Inc.’s Sogroya (somapacitanbeco) for the replacement of growth hormone in adults with growth hormone deficiency in August 2020, it became the only long-acting agent on the market. A survey by Zitter Insights shows that many endocrinologists expect to shift prescribing to such agents from the short-acting growth hormones.  

To read the full Reality Check on Growth Hormone Deficiency treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing